Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies

NCT00526838 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT00526838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2007
Completion date
December 31, 2010
Enrollment
84 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, lymphoma